Document Detail

Growth hormone deficiency and vascular risk.
MedLine Citation:
PMID:  12100064     Owner:  NLM     Status:  MEDLINE    
The importance of growth hormone deficiency (GHD) in adult life has become more apparent over the last decade. As well as a distinct clinical syndrome there is a significant excess risk of cardiovascular disease. Although it is difficult to ascertain what part is played by the original pituitary disorder and the concomitant replacement hormonal therapies, there is clear evidence that GHD is associated with known cardiovascular risk factors such as body shape, lipid profile, insulin resistance, blood pressure, vessel wall morphology and haemostatic factors. Novel means of assessing vascular risk such as pulse wave velocity and flow-mediated dilatation can also estimate the risk without invasive procedures. The role of possible mediators of endothelial function such as nitric oxide and free radicals is being investigated further. Replacement of GH in GH-deficient patients leads to many effects on the above indices, some but not all of which are associated with reduced vascular risk. Long-term follow-up studies of morbidity and mortality are required for an accurate assessment of the beneficial effects of therapy.
Roland W McCallum; John R Petrie; Anna F Dominiczak; John M C Connell
Related Documents :
10999494 - Myocardial infarction in women: a critical appraisal of gender differences in outcomes.
2080194 - Steroid sex hormones and cardiovascular function in healthy males and females: a correl...
21782504 - Htlv infection among foreign pregnant women living in spain.
10190334 - Practitioner review: electroconvulsive therapy in adolescents.
19668924 - Applicability of framingham risk equations for studying a low-income mexican population.
23817584 - Medicinal nicotine nonuse: smokers' rationales for past behavior and intentions to try ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical endocrinology     Volume:  57     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-08     Completed Date:  2002-09-10     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-24     Citation Subset:  IM    
Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / etiology*,  prevention & control
Endothelium, Vascular / physiopathology
Great Britain
Human Growth Hormone / therapeutic use
Hypertension / complications
Pituitary Diseases / complications*,  drug therapy,  epidemiology
Somatostatin / deficiency*
Vascular Resistance
Reg. No./Substance:
12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance.
Next Document:  Serum leptin concentrations of patients with sequential thyroid function changes.